新型MIRUS系统用于术后ICU患者短期七氟烷镇静
本研究为前瞻性干预研究,于2016年2月至12月在一外科ICU纳入62例需机械通气和镇静的术后患者,使用MIRUS系统给予七氟烷,目标Richmond躁动-镇静量表(RASS)为-3至-5,通过调节最低肺泡有效浓度(MAC)实现。结果显示无技术故障,RASS中位数-4.5,MAC中位数0.45%,平均吸气与呼气七氟烷浓度分别为0.79%和0.76%,中位觉醒时间4分钟,中位给药时长3.33小时(范围1-19小时),平均消耗7.89 mL/hr,血流动力学稳定,无肝肾损伤实验室证据。环境七氟烷浓度在基线、S1和S2分别为0.10、0.17和0.15 ppm,远低于推荐阈值(<5 ppm)。作者认为MIRUS系统是术后ICU患者短期七氟烷镇静有前景且安全的替代方案,但需更异质人群和更长镇静时间的研究证实。
要点
- 62例术后ICU机械通气患者使用MIRUS系统七氟烷镇静,目标RASS -3至-5,无技术故障发生。
- 七氟烷MAC中位数0.45%,平均吸气浓度0.79%、呼气浓度0.76%,RASS中位数-4.5。
- 中位觉醒时间4分钟,中位给药时长3.33小时(范围1-19小时),平均消耗7.89 mL/hr。
- 血流动力学稳定,无实验室数据提示肝或肾损伤或功能障碍。
- 环境七氟烷浓度基线0.10 ppm、S1 0.17 ppm、S2 0.15 ppm,远低于推荐阈值(<5 ppm)。
适用人群与场景
- 术后需入住ICU、接受机械通气和镇静的患者。
- 研究在外科ICU进行,时间为2016年2月至2016年12月。
诊断标准与关键阈值
- 镇静目标为Richmond躁动-镇静量表(RASS)从-3至-5,通过调节最低肺泡有效浓度(MAC)实现。
处置流程与药物剂量
- 使用MIRUS系统(Pall International, Sarl, Fribourg, Switzerland)给予七氟烷,目标RASS -3至-5,通过调节MAC实现。
- 七氟烷给药中位MAC为0.45%(IQR 0.4-0.53%),平均吸气浓度0.79%(SD 0.24%)、呼气浓度0.76%(SD 0.18%)。
- 中位给药时长3.33小时(IQR 2.33-5.75小时),范围1-19小时,平均消耗7.89 mL/hr(SD 2.99)。
研究设计与关键结果
- 研究类型:前瞻性干预研究;样本量62例;人群:术后ICU机械通气镇静患者;干预:MIRUS系统七氟烷镇静,目标RASS -3至-5。
- 无技术故障发生;RASS中位数-4.5(IQR -5至-3.6)。
- 中位觉醒时间4分钟(IQR 2.2-5分钟);中位给药时长3.33小时(IQR 2.33-5.75小时),范围1-19小时;平均消耗7.89 mL/hr(SD 2.99)。
- 血流动力学保持稳定,无实验室数据提示肝或肾损伤或功能障碍。
- 环境七氟烷浓度:基线0.10 ppm(IQR 0.07-0.15),S1 0.17 ppm(IQR 0.14-0.27),S2 0.15 ppm(IQR 0.07-0.19),均远低于推荐阈值(<5 ppm)。
证据类型、等级与局限
- 证据类型:前瞻性干预研究。
- 局限:需扩展至更异质人群和更长镇静时间的研究以证实这些观察结果。
对床旁实践的改变
- 作者认为MIRUS系统是术后ICU患者短期七氟烷镇静有前景且安全的替代方案。
- 作者指出需扩展至更异质人群和更长镇静时间的研究以证实这些观察结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the feasibility and safety of the MIRUS system (Pall International, Sarl, Fribourg, Switzerland) for sedation with sevoflurane for postsurgical ICU patients and to evaluate atmospheric pollution during sedation.
DESIGN: Prospective interventional study.
SETTING: Surgical ICU. February 2016 to December 2016.
PATIENTS: Postsurgical patients requiring ICU admission, mechanical ventilation, and sedation.
INTERVENTIONS: Sevoflurane was administered with the MIRUS system targeted to a Richmond Agitation Sedation Scale from -3 to -5 by adaptation of minimum alveolar concentration.
MEASUREMENTS AND MAIN RESULTS: Data collected included Richmond Agitation Sedation Scale, minimum alveolar concentration, inspired and expired sevoflurane fraction, wake-up times, duration of sedation, sevoflurane consumption, respiratory and hemodynamic data, Simplified Acute Physiology Score II, Sepsis-related Organ Failure Assessment, and laboratory data and biomarkers of organ injury. Atmospheric pollution was monitored at different sites: before sevoflurane delivery (baseline) and during sedation with the probe 15 cm up to the MIRUS system (S1) and 15 cm from the filter-Reflector group (S2). Sixty-two patients were enrolled in the study. No technical failure occurred. Median Richmond Agitation Sedation Scale was -4.5 (interquartile range, -5 to -3.6) with sevoflurane delivered at a median minimum alveolar concentration of 0.45% (interquartile range, 0.4-0.53) yielding a mean inspiratory and expiratory concentrations of 0.79% (SD, 0.24) and 0.76% (SD, 0.18), respectively. Median awakening time was 4 minutes (2.2-5 min). Median duration of sevoflurane administration was 3.33 hours (2.33-5.75 hr), range 1-19 hours with a mean consumption of 7.89 mL/hr (SD, 2.99). Hemodynamics remained stable over the study period, and no laboratory data indicated liver or kidney injury or dysfunction. Median sevoflurane room air concentration was 0.10 parts per million (interquartile range, 0.07-0.15), 0.17 parts per million (interquartile range, 0.14-0.27), and 0.15 parts per million (interquartile range, 0.07-0.19) at baseline, S1, and S2, respectively.
CONCLUSIONS: The MIRUS system is a promising and safe alternative for short-term sedation with sevoflurane of ICU patients. Atmospheric pollution is largely below the recommended thresholds (< 5 parts per million). Studies extended to more heterogeneous population of patients undergoing longer duration of sedation are needed to confirm these observations.
参考来源
- Romagnoli S, Chelazzi C, Villa G, et al. The New MIRUS System for Short-Term Sedation in Postsurgical ICU Patients. Crit Care Med. 2017. PMID: 28441236. doi:10.1097/CCM.0000000000002465
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。